MedTrace Logo

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

NCT03587558 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2018-07-18

No results posted yet for this study

Summary

Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in patients with heart failure. It is suggested that one of the mechanisms is its ability to block store overload-induced Calcium release which activates spontaneous calcium release by Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with calcium overload due to activation of Ryanodine receptors. The aim of this study is to evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular tachycardia(VT) originating from outflow tract.

Conditions

  • Ventricular Premature Complexes
  • Outflow Tract
  • Carvedilol

Interventions

DRUG

Carvedilol

Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.

DRUG

Flecainide

Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical Corp.

    collaborator INDUSTRY

  • Keimyung University Dongsan Medical Center

    lead OTHER

Principal Investigators

  • Seongwook Han, M.D., Ph.D. · Keimyung University Dongsan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587558 on ClinicalTrials.gov